Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06145048
PHASE2

Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

Sponsor: Vergent Bioscience, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 2, multi-center, open-label study to evaluate the safety and efficacy of VGT-309, a tumor-targeted, activatable fluorescent imaging agent, in subjects undergoing surgery for proven or suspected cancer in the lung. Approximately 100 subjects will be enrolled to ensure at least 86 subjects are evaluable with the option to expand enrollment by protocol amendment if deemed necessary by the DSC to meet primary and/or secondary objectives.

Official title: A Phase 2, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of VGT-309, a Tumor-Targeted, Activatable Fluorescent Imaging Agent, in Subjects Undergoing Surgery for Cancer in the Lung

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

89

Start Date

2023-10-05

Completion Date

2025-02-20

Last Updated

2026-05-13

Healthy Volunteers

No

Interventions

DRUG

VGT-309

Intravenous drug to be given over 15-20 minutes by syringe pump.

Locations (6)

City of Hope National Medical Center

Duarte, California, United States

Orlando Health Cancer Institute

Orlando, Florida, United States

Mayo Clinic

Rochester, Minnesota, United States

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

St. Vincent's Hospital

Melbourne, Victoria, Australia